Communiqués Pulmatrix, Inc.

Actions

PULM

US74584P3010

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
1,660 ^USD	0,00%		-4,60%	-25,56%

15/05	Pulmatrix, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
21/04	Pulmatrix annonce la clôture de son émission d'actions privilégiées dans le cadre de son projet de fusion	RE

Communiqués

15/05	Pulmatrix Announces First Quarter 2026 Financial Results	PR
21/04	Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger	PR
13/04	PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders	BU
26/03	Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan	PR
02/03	Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities	PR
26/02	Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results	PR
18/12	Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives	PR
16/10/25	Pulmatrix : Quarterly Report for Quarter Ending September 30, 2025 (Form 10-Q)	PU
16/10/25	Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets	PR
06/08/25	Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets	PR
15/05/25	Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets	PR
09/05/25	PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM	BU
24/03/25	Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets	AQ
21/03/25	Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets	PR
22/01/25	Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain	AQ
15/11/24	PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM	BU
13/11/24	Pulmatrix : and Cullgen Announce Proposed Merger Form 8 K	PU
11/11/24	Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update	AQ
08/11/24	Pulmatrix : Announces Third Quarter 2024 Financial Results and Provides Corporate Update Form 8 K	PU
14/08/24	Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update	AQ
30/05/24	Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	AQ
16/05/24	Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine	AQ
15/05/24	Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K	PU
13/05/24	Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update	AQ
09/01/24	Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives	AQ